PCEC Launches Lucerum:

A Dedicated Commercialization Company for EEG Analytics

We are excited to announce that PCEC has formed Lucerum,Inc., to advance our cutting-edge EEG analytics platform. This strategic move allows Lucerum to focus exclusively on bringing our powerful neuroanalytics technology to market, accelerating adoption across clinical, research, and commercial applications.

Lucerum will build on PCEC’s deep expertise in preclinical and clinical EEG analytics, providing scalable, cloud-based solutions for biopharma, CROs, clinics, and neuroscience researchers. The new entity ensures greater agility in product development, partnerships, and customer engagement, allowing us to meet the growing demand for precision EEG insights.

As Lucerum takes this next step, we remain committed to delivering innovative, high-impact solutions that transform EEG data into actionable insights. Stay tuned for more updates as we expand our capabilities and partnerships.

For inquiries and collaboration opportunities, please contact us here or through the Lucerum website.

Currently in Development

The first clinical database platform for EEG neuroanalytics empowering clinicians to gain unparalleled insights into brain function, predict drug or treatment response, and guide therapies.

Unlocking precision in brain health

transforming personalized medicine

LucerumCarto integrates EEG neuroanalytics with neuropsychiatric assessments and treatment outcomes to create a robust framework for understanding and treating brain disorders.

By leveraging the strengths of qEEG aligned with neuropsychiatric evaluations clinicians can achieve a higher level of diagnostic accuracy. This not only ensures that patients receive the most appropriate and effective treatments for neurological and psychiatric conditions but also integrates research tools and database analytics into the day-to-day clinical practice.

This integrated diagnostic approach is particularly effective in tailoring interventions to individual needs and monitoring their impacts, as well as understanding the impact of therapies or neuromodulation.

  • User-friendly portal built for clinicians

  • Secure HIPAA compliant patient database

  • State-of-the-art EEG analytical tools and advanced brain mapping

  • Connectomics

  • Neurotransmitter predictions

  • Multimodal visualization interface: qEEG, neuropsychiatric tests, symptoms, outcomes

  • TMS guidance and EEG-neuromodulation

  • Embedded statistics and AI/ML tools

  • Interoperability and easy retrieval of standardized data

NEUROTRANSMITTER

PREDICTIONS

Aligning functional and molecular brain-mapping

to accelerate personalized medicine

EEG-based Neurotransmitter Dominance

A Unique Approach Pioneered by PCEC

We are excited to play a pioneering role in EEG-neuroimaging applications to precision psychiatry. We have recently completed the development of a series of unique cross-species algorithms relating neurotransmitter contribution to changes in neural oscillations due to a drug or therapeutic intervention. Based on these groundbreaking innovative applications of key neuroscience and neuroimaging advances, LucerumCarto platform will empower our clinician partners to better understand the brain networks dysregulated and increase the precision of diagnostic and medication choice. We have built a seamless link between our research platform LucerumKey and our clinical platform LucerumCarto, to allow future cutting-edge applications of artificial intelligence on large data and a variety of biomarker approaches.

Presently networking with innovators and investors

We value collaboration in research and development. LucermCarto will enable partner companies to build unique research or commercial applications harnessing the power of platform-based EEG neuroimaging and neurotransmitter predictions. Partner with us for AI-enabled custom neuroimaging research.